{"name":"Boryung Pharmaceutical Co., Ltd","slug":"boryung-pharmaceutical-co-ltd","ticker":"","exchange":"","domain":"boryung.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":22,"colorKey":"immunology","drugs":[{"name":"BR1019B-1","genericName":"BR1019B-1","slug":"br1019b-1","indication":"Hypertension","status":"phase_3"},{"name":"BR1400-3","genericName":"BR1400-3","slug":"br1400-3","indication":"Hypertension","status":"phase_2"},{"name":"BR1400-A","genericName":"BR1400-A","slug":"br1400-a","indication":"Hypertension","status":"phase_2"},{"name":"Fimasartan and Rosuvastatin","genericName":"Fimasartan and Rosuvastatin","slug":"fimasartan-and-rosuvastatin","indication":"Hypertension with dyslipidemia","status":"phase_3"},{"name":"Treatment T","genericName":"Treatment T","slug":"treatment-t","indication":"Hypertension","status":"marketed"},{"name":"BR1018A-1","genericName":"BR1018A-1","slug":"br1018a-1","indication":"Hypertension","status":"phase_3"},{"name":"BR1018B-1","genericName":"BR1018B-1","slug":"br1018b-1","indication":"Hypertension","status":"phase_3"},{"name":"BR1018C-1","genericName":"BR1018C-1","slug":"br1018c-1","indication":"Hypertension","status":"phase_3"},{"name":"BR1019A-1","genericName":"BR1019A-1","slug":"br1019a-1","indication":"Hypertension","status":"phase_3"},{"name":"BR1019C-1","genericName":"BR1019C-1","slug":"br1019c-1","indication":"Hypertension","status":"phase_3"},{"name":"BR1400-1","genericName":"BR1400-1","slug":"br1400-1","indication":"Hypertension","status":"phase_2"},{"name":"BR1400-C","genericName":"BR1400-C","slug":"br1400-c","indication":"Hypertension","status":"phase_2"},{"name":"Fimasartan + Indapamide","genericName":"Fimasartan + Indapamide","slug":"fimasartan-indapamide","indication":"Essential hypertension","status":"phase_3"},{"name":"Fimasartan and Amlodipine","genericName":"Fimasartan and Amlodipine","slug":"fimasartan-and-amlodipine","indication":"Hypertension","status":"phase_3"},{"name":"Fimasartan or Fimasartan/Hydrochlorothiazide","genericName":"Fimasartan or Fimasartan/Hydrochlorothiazide","slug":"fimasartan-or-fimasartan-hydrochlorothiazide","indication":"Hypertension","status":"phase_3"},{"name":"Fimasartan, Rosuvastatin","genericName":"Fimasartan, Rosuvastatin","slug":"fimasartan-rosuvastatin","indication":"Hypertension with dyslipidemia","status":"phase_3"},{"name":"Fimasartan/Amlodipine combination","genericName":"Fimasartan/Amlodipine combination","slug":"fimasartan-amlodipine-combination","indication":"Hypertension","status":"phase_3"},{"name":"Fimasartan/Amlodipine, Rosuvastatin","genericName":"Fimasartan/Amlodipine, Rosuvastatin","slug":"fimasartan-amlodipine-rosuvastatin","indication":"Hypertension and dyslipidemia in patients requiring combination therapy","status":"phase_3"},{"name":"Fimasartan/HCTZ combination","genericName":"Fimasartan/HCTZ combination","slug":"fimasartan-hctz-combination","indication":"Hypertension","status":"phase_3"},{"name":"Losartan (Control)","genericName":"Losartan (Control)","slug":"losartan-control","indication":"Hypertension","status":"phase_3"},{"name":"Perindopril or Perindopril/Indapamide","genericName":"Perindopril or Perindopril/Indapamide","slug":"perindopril-or-perindopril-indapamide","indication":"Hypertension","status":"phase_3"},{"name":"Treatment R","genericName":"Treatment R","slug":"treatment-r","indication":"Hypertension","status":"marketed"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":19,"colorKey":"oncology","drugs":[{"name":"BR1019A","genericName":"BR1019A","slug":"br1019a","indication":"Other","status":"phase_3"},{"name":"BR1019B","genericName":"BR1019B","slug":"br1019b","indication":"Other","status":"phase_3"},{"name":"BR1400-4","genericName":"BR1400-4","slug":"br1400-4","indication":"Other","status":"phase_2"},{"name":"BR5402B","genericName":"BR5402B","slug":"br5402b","indication":"Other","status":"phase_2"},{"name":"DTaP vaccine and IPV vaccine","genericName":"DTaP vaccine and IPV vaccine","slug":"dtap-vaccine-and-ipv-vaccine","indication":"Prevention of diphtheria, tetanus, pertussis, and poliomyelitis in infants and children","status":"phase_3"},{"name":"Aspirin enteric coated pellests 100mg","genericName":"Aspirin enteric coated pellests 100mg","slug":"aspirin-enteric-coated-pellests-100mg","indication":"Other","status":"marketed"},{"name":"BR1015-1","genericName":"BR1015-1","slug":"br1015-1","indication":"Other","status":"phase_1"},{"name":"BR1016C","genericName":"BR1016C","slug":"br1016c","indication":"Other","status":"phase_1"},{"name":"BR101801","genericName":"BR101801","slug":"br101801","indication":"Other","status":"phase_2"},{"name":"BR1018B","genericName":"BR1018B","slug":"br1018b","indication":"Other","status":"phase_3"},{"name":"BR1018C","genericName":"BR1018C","slug":"br1018c","indication":"Other","status":"phase_3"},{"name":"BR1019C","genericName":"BR1019C","slug":"br1019c","indication":"Other","status":"phase_3"},{"name":"BR1400-2","genericName":"BR1400-2","slug":"br1400-2","indication":"Other","status":"phase_2"},{"name":"BR1400-5","genericName":"BR1400-5","slug":"br1400-5","indication":"Other","status":"phase_2"},{"name":"BR1400-B","genericName":"BR1400-B","slug":"br1400-b","indication":"Other","status":"phase_2"},{"name":"BR5402C-1","genericName":"BR5402C-1","slug":"br5402c-1","indication":"Other","status":"phase_2"},{"name":"BR5402D","genericName":"BR5402D","slug":"br5402d","indication":"Other","status":"phase_2"},{"name":"BR5402D-1","genericName":"BR5402D-1","slug":"br5402d-1","indication":"Other","status":"phase_2"},{"name":"JE vaccine","genericName":"JE vaccine","slug":"je-vaccine","indication":"Prevention of Japanese encephalitis in endemic regions","status":"phase_3"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"cardiovascular","drugs":[{"name":"BR5402A","genericName":"BR5402A","slug":"br5402a","indication":"Type 2 diabetes","status":"phase_2"},{"name":"BR5402A-1","genericName":"BR5402A-1","slug":"br5402a-1","indication":"Hypercholesterolemia","status":"phase_2"},{"name":"BR5402B-1","genericName":"BR5402B-1","slug":"br5402b-1","indication":"Type 2 diabetes","status":"phase_2"},{"name":"Dapagliflozin/Pioglitazone","genericName":"Dapagliflozin/Pioglitazone","slug":"dapagliflozin-pioglitazone","indication":"Type 2 diabetes mellitus","status":"marketed"},{"name":"Dapagliflozin/Sitagliptin","genericName":"Dapagliflozin/Sitagliptin","slug":"dapagliflozin-sitagliptin","indication":"Type 2 diabetes mellitus","status":"marketed"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"neuroscience","drugs":[{"name":"BR5402C","genericName":"BR5402C","slug":"br5402c","indication":"Metastatic non-small cell lung cancer","status":"phase_2"},{"name":"BR1018A","genericName":"BR1018A","slug":"br1018a","indication":"Oncology indication (specific indication not publicly disclosed)","status":"phase_3"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"infectious","drugs":[{"name":"Havrix Inj","genericName":"Havrix Inj","slug":"havrix-inj","indication":"Prevention of hepatitis A infection in adults and children","status":"phase_3"}]}],"pipeline":[{"name":"BR1019A","genericName":"BR1019A","slug":"br1019a","phase":"phase_3","mechanism":"BR1019A is an investigational therapeutic in phase 3 development by Boryung Pharmaceutical, but its specific mechanism of action is not publicly disclosed.","indications":[],"catalyst":""},{"name":"BR1019B","genericName":"BR1019B","slug":"br1019b","phase":"phase_3","mechanism":"BR1019B is an investigational therapeutic in phase 3 development by Boryung Pharmaceutical, but its specific mechanism of action is not publicly disclosed.","indications":[],"catalyst":""},{"name":"BR1019B-1","genericName":"BR1019B-1","slug":"br1019b-1","phase":"phase_3","mechanism":"BR1019B-1 is a small molecule drug that targets the renin-angiotensin system.","indications":["Hypertension","Heart failure"],"catalyst":""},{"name":"BR1400-3","genericName":"BR1400-3","slug":"br1400-3","phase":"phase_2","mechanism":"BR1400-3 is a small molecule that targets the renin-angiotensin system.","indications":["Hypertension"],"catalyst":""},{"name":"BR1400-4","genericName":"BR1400-4","slug":"br1400-4","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"BR1400-A","genericName":"BR1400-A","slug":"br1400-a","phase":"phase_2","mechanism":"BR1400-A is a small molecule that targets the renin-angiotensin system.","indications":["Hypertension"],"catalyst":""},{"name":"BR5402A","genericName":"BR5402A","slug":"br5402a","phase":"phase_2","mechanism":"BR5402A is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"BR5402A-1","genericName":"BR5402A-1","slug":"br5402a-1","phase":"phase_2","mechanism":"BR5402A-1 is a small molecule that targets the HMG-CoA reductase enzyme.","indications":["Hypercholesterolemia"],"catalyst":""},{"name":"BR5402B","genericName":"BR5402B","slug":"br5402b","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"BR5402C","genericName":"BR5402C","slug":"br5402c","phase":"phase_2","mechanism":"BR5402C is a small molecule that targets the HIF-1α pathway.","indications":["Metastatic non-small cell lung cancer"],"catalyst":""},{"name":"DTaP vaccine and IPV vaccine","genericName":"DTaP vaccine and IPV vaccine","slug":"dtap-vaccine-and-ipv-vaccine","phase":"phase_3","mechanism":"This combination vaccine stimulates the immune system to produce antibodies and cellular immunity against diphtheria, tetanus, pertussis, and poliovirus.","indications":["Prevention of diphtheria, tetanus, pertussis, and poliomyelitis in infants and children"],"catalyst":""},{"name":"Fimasartan and Rosuvastatin","genericName":"Fimasartan and Rosuvastatin","slug":"fimasartan-and-rosuvastatin","phase":"phase_3","mechanism":"Fimasartan blocks angiotensin II receptors to lower blood pressure, while rosuvastatin inhibits HMG-CoA reductase to reduce cholesterol synthesis.","indications":["Hypertension with dyslipidemia","Cardiovascular risk reduction in patients requiring both antihypertensive and lipid-lowering therapy"],"catalyst":""},{"name":"Treatment T","genericName":"Treatment T","slug":"treatment-t","phase":"marketed","mechanism":"Treatment T is a calcium channel blocker that works by inhibiting the influx of calcium ions into cardiac and vascular smooth muscle cells.","indications":["Hypertension","Angina pectoris"],"catalyst":""},{"name":"Aspirin enteric coated pellests 100mg","genericName":"Aspirin enteric coated pellests 100mg","slug":"aspirin-enteric-coated-pellests-100mg","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"BR1015-1","genericName":"BR1015-1","slug":"br1015-1","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"BR1016C","genericName":"BR1016C","slug":"br1016c","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"BR101801","genericName":"BR101801","slug":"br101801","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"BR1018A","genericName":"BR1018A","slug":"br1018a","phase":"phase_3","mechanism":"BR1018A is an investigational therapeutic targeting immune checkpoint pathways to enhance anti-tumor immunity.","indications":["Oncology indication (specific indication not publicly disclosed)"],"catalyst":""},{"name":"BR1018A-1","genericName":"BR1018A-1","slug":"br1018a-1","phase":"phase_3","mechanism":"BR1018A-1 is a small molecule drug that targets the renin-angiotensin system.","indications":["Hypertension","Heart failure"],"catalyst":""},{"name":"BR1018B","genericName":"BR1018B","slug":"br1018b","phase":"phase_3","mechanism":"BR1018B is a therapeutic agent in phase 3 development by Boryung Pharmaceutical, but its specific mechanism of action is not publicly disclosed.","indications":[],"catalyst":""},{"name":"BR1018B-1","genericName":"BR1018B-1","slug":"br1018b-1","phase":"phase_3","mechanism":"BR1018B-1 is a small molecule that targets the renin-angiotensin system.","indications":["Hypertension","Heart failure"],"catalyst":""},{"name":"BR1018C","genericName":"BR1018C","slug":"br1018c","phase":"phase_3","mechanism":"BR1018C is a therapeutic agent in phase 3 development by Boryung Pharmaceutical, but its specific mechanism of action is not publicly disclosed.","indications":[],"catalyst":""},{"name":"BR1018C-1","genericName":"BR1018C-1","slug":"br1018c-1","phase":"phase_3","mechanism":"BR1018C-1 is a small molecule that targets the renin-angiotensin system.","indications":["Hypertension"],"catalyst":""},{"name":"BR1019A-1","genericName":"BR1019A-1","slug":"br1019a-1","phase":"phase_3","mechanism":"BR1019A-1 is a small molecule that targets the renin-angiotensin system.","indications":["Hypertension"],"catalyst":""},{"name":"BR1019C","genericName":"BR1019C","slug":"br1019c","phase":"phase_3","mechanism":"BR1019C is an investigational therapeutic agent in phase 3 development by Boryung Pharmaceutical, but its specific mechanism of action is not publicly disclosed.","indications":[],"catalyst":""},{"name":"BR1019C-1","genericName":"BR1019C-1","slug":"br1019c-1","phase":"phase_3","mechanism":"BR1019C-1 is a small molecule drug that targets the renin-angiotensin system.","indications":["Hypertension","Heart failure"],"catalyst":""},{"name":"BR1400-1","genericName":"BR1400-1","slug":"br1400-1","phase":"phase_2","mechanism":"BR1400-1 is a small molecule that targets the renin-angiotensin system.","indications":["Hypertension"],"catalyst":""},{"name":"BR1400-2","genericName":"BR1400-2","slug":"br1400-2","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"BR1400-5","genericName":"BR1400-5","slug":"br1400-5","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"BR1400-B","genericName":"BR1400-B","slug":"br1400-b","phase":"phase_2","mechanism":"BR1400-B is an investigational therapeutic in phase 2 development by Boryung Pharmaceutical with an undisclosed or proprietary mechanism of action.","indications":[],"catalyst":""},{"name":"BR1400-C","genericName":"BR1400-C","slug":"br1400-c","phase":"phase_2","mechanism":"BR1400-C is a small molecule that targets the renin-angiotensin system.","indications":["Hypertension"],"catalyst":""},{"name":"BR5402B-1","genericName":"BR5402B-1","slug":"br5402b-1","phase":"phase_2","mechanism":"BR5402B-1 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"BR5402C-1","genericName":"BR5402C-1","slug":"br5402c-1","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"BR5402D","genericName":"BR5402D","slug":"br5402d","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"BR5402D-1","genericName":"BR5402D-1","slug":"br5402d-1","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Dapagliflozin/Pioglitazone","genericName":"Dapagliflozin/Pioglitazone","slug":"dapagliflozin-pioglitazone","phase":"marketed","mechanism":"This combination drug reduces blood glucose by inhibiting SGLT2 to increase urinary glucose excretion and activating PPAR-γ to improve insulin sensitivity.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"Dapagliflozin/Sitagliptin","genericName":"Dapagliflozin/Sitagliptin","slug":"dapagliflozin-sitagliptin","phase":"marketed","mechanism":"This combination drug lowers blood glucose by inhibiting SGLT2 to increase urinary glucose excretion and inhibiting DPP-4 to increase incretin levels.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"Fimasartan + Indapamide","genericName":"Fimasartan + Indapamide","slug":"fimasartan-indapamide","phase":"phase_3","mechanism":"Fimasartan blocks angiotensin II receptors to lower blood pressure, while indapamide acts as a thiazide-like diuretic to reduce fluid volume and further decrease blood pressure.","indications":["Essential hypertension"],"catalyst":""},{"name":"Fimasartan and Amlodipine","genericName":"Fimasartan and Amlodipine","slug":"fimasartan-and-amlodipine","phase":"phase_3","mechanism":"Fimasartan blocks angiotensin II receptors to lower blood pressure, while amlodipine relaxes blood vessels by blocking calcium channels, providing dual antihypertensive action.","indications":["Hypertension"],"catalyst":""},{"name":"Fimasartan or Fimasartan/Hydrochlorothiazide","genericName":"Fimasartan or Fimasartan/Hydrochlorothiazide","slug":"fimasartan-or-fimasartan-hydrochlorothiazide","phase":"phase_3","mechanism":"Fimasartan is an angiotensin II receptor blocker (ARB) that selectively antagonizes the AT1 receptor to reduce vasoconstriction and lower blood pressure.","indications":["Hypertension","Hypertension (combination therapy with hydrochlorothiazide)"],"catalyst":""},{"name":"Fimasartan, Rosuvastatin","genericName":"Fimasartan, Rosuvastatin","slug":"fimasartan-rosuvastatin","phase":"phase_3","mechanism":"Fimasartan is an angiotensin II receptor blocker that reduces blood pressure, while rosuvastatin is a statin that lowers cholesterol; together they address hypertension and dyslipidemia.","indications":["Hypertension with dyslipidemia","Cardiovascular risk reduction in patients requiring both antihypertensive and lipid-lowering therapy"],"catalyst":""},{"name":"Fimasartan/Amlodipine combination","genericName":"Fimasartan/Amlodipine combination","slug":"fimasartan-amlodipine-combination","phase":"phase_3","mechanism":"Fimasartan blocks angiotensin II receptors to lower blood pressure, while amlodipine blocks calcium channels to relax blood vessels, providing dual antihypertensive action.","indications":["Hypertension"],"catalyst":""},{"name":"Fimasartan/Amlodipine, Rosuvastatin","genericName":"Fimasartan/Amlodipine, Rosuvastatin","slug":"fimasartan-amlodipine-rosuvastatin","phase":"phase_3","mechanism":"This combination drug lowers blood pressure through angiotensin II receptor blockade and calcium channel inhibition, while simultaneously reducing cholesterol via HMG-CoA reductase inhibition.","indications":["Hypertension and dyslipidemia in patients requiring combination therapy"],"catalyst":""},{"name":"Fimasartan/HCTZ combination","genericName":"Fimasartan/HCTZ combination","slug":"fimasartan-hctz-combination","phase":"phase_3","mechanism":"Fimasartan blocks angiotensin II type 1 receptors to lower blood pressure, while hydrochlorothiazide acts as a thiazide diuretic to reduce fluid volume and further decrease blood pressure.","indications":["Hypertension"],"catalyst":""},{"name":"Havrix Inj","genericName":"Havrix Inj","slug":"havrix-inj","phase":"phase_3","mechanism":"Havrix is an inactivated hepatitis A vaccine that stimulates the immune system to produce antibodies against hepatitis A virus.","indications":["Prevention of hepatitis A infection in adults and children"],"catalyst":""},{"name":"JE vaccine","genericName":"JE vaccine","slug":"je-vaccine","phase":"phase_3","mechanism":"JE vaccine stimulates the immune system to produce antibodies and cellular immunity against Japanese encephalitis virus.","indications":["Prevention of Japanese encephalitis in endemic regions"],"catalyst":""},{"name":"Losartan (Control)","genericName":"Losartan (Control)","slug":"losartan-control","phase":"phase_3","mechanism":"Losartan blocks angiotensin II type 1 (AT1) receptors, preventing vasoconstriction and aldosterone release to lower blood pressure.","indications":["Hypertension","Diabetic nephropathy in patients with type 2 diabetes","Heart failure with reduced ejection fraction","Post-myocardial infarction"],"catalyst":""},{"name":"Perindopril or Perindopril/Indapamide","genericName":"Perindopril or Perindopril/Indapamide","slug":"perindopril-or-perindopril-indapamide","phase":"phase_3","mechanism":"Perindopril is an angiotensin-converting enzyme (ACE) inhibitor that blocks the conversion of angiotensin I to angiotensin II, thereby reducing blood pressure and heart workload.","indications":["Hypertension","Heart failure"],"catalyst":""},{"name":"Treatment R","genericName":"Treatment R","slug":"treatment-r","phase":"marketed","mechanism":"Treatment R is a calcium channel blocker that works by relaxing blood vessels and reducing blood pressure.","indications":["Hypertension"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxQWkpvT1pGOEZIN0RGUzBYSnIySUVXZ1ZwSktrM3RIZVRTMTJzMHB4QnhSb3JKUTBaTDhTS2lNRWdrLVBJY0lWVG84NzVKZHBSWUZER0NKWVhpbnlucjJxMzVDbnc0ZGRUbmk0VHM3aEZOZ1RzSDZLaUItZEZBb0V4ddIBlAFBVV95cUxQb0lDODZPemhRVkhZWHd2bXBMSVZQYXp6Ukx0TXAxTGZCb2Zmb3VoOExEbjdzYlRsUTQzT3VTT3BpQWNRMWVEeXZUWTJ1MG1fUlBBczFWVFdIQ3N0ZlpvLS1vQXdPUFo4dnUwSDlGRTVSR2FNa3RsdjFSUWl6eldFbUZNRGxVRzV3c1U1Qk9wVjN0RVBU?oc=5","date":"2026-04-06","type":"pipeline","source":"Chosunbiz","summary":"Korea pharma shifts to external hires as price cuts push global R&D - CHOSUNBIZ - Chosunbiz","headline":"Korea pharma shifts to external hires as price cuts push global R&D - CHOSUNBIZ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE90bDZZXzhMOHFEWFdsZFVYZFVqLXQ2YzVfdEY5aGFRamlaZEVEUHk2LWxCOWc0OG9qQVJlSENIYXZJYWR1S2pqdVYzeThKRkRvTW1NZF9kQk5FYWl2LTcyamZnbUdfTVZQSkFYamxn0gFyQVVfeXFMUDhKa1B0TktQSkl0cnZpbkFZdmhnNkRXVnBzSHhUTUNNVk5FVDJma3l0TWVobkNuNWxuRjdwallMTHppb0lDbzZWQkZRbEgxeXFuSG9hZmZEUm1GZFYtR09QRUN0X3hpZmgzY2lOcVB5amRB?oc=5","date":"2026-03-04","type":"deal","source":"koreabiomed.com","summary":"Boryung adds Xpovio to blood cancer portfolio under Antengene license deal - koreabiomed.com","headline":"Boryung adds Xpovio to blood cancer portfolio under Antengene license deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTFBMS3hjWTNIcE5DVkxYeE54OF95b0xYNHZjUFE2VkNKS21oSXktRDh2S1dEQXhOTUM0NkNRZ0xhOHFTRU9CUkVzcms5SUJRejRRV1dIWHdRNURzWVh4VHlUMm9lRUNQQ3N6d0NxLUhR0gFyQVVfeXFMUEp5WTRSU0pkYjZyNXozVHUtd1NlSVJMd3QtSXFGQld2cXF6eEI0SEhaU1l3enROTUgwcTlXVXdTeFF0LWFWOFUydGxpMzM0WDdJcS1xd2RkZWM5dlJxUmdTdk8tYWFXVWNCTGdpNXNfOGRB?oc=5","date":"2025-03-31","type":"pipeline","source":"koreabiomed.com","summary":"Boryung CEO charts bold future with space healthcare vision, reinforces pharma core - koreabiomed.com","headline":"Boryung CEO charts bold future with space healthcare vision, reinforces pharma core","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgJBVV95cUxQLUdGNExlVk1Yb25WMVhZWUlQUzgteV93WGRaSHU4WWZzMDFUYURLQXV5dFdHM3JTcERzSVQ5eUlLOFRSTXFsak8xdFJ4RmpHblB6YXJWY0tXMnhrQWluUk5OTkRqWTZvWHB0UkUyMndISW9XSS1tNDhnTDVnZmVxZm1lWUVLM3VVb2Y0dzJ2ZDExNWlhNk84RERxRkJSY2RubzhfSHZPZ3JpQ1NhSWV3ODltTlc3TF9ZWlV4LXFNWV9EdFlOT1RQNnFGeVotT3l3LWhmd2Z1Y19DcmtfQzJqdDlSaFlsZWJhWmlPMVluVkIzTmRPcTQxcDZ1UkhicGVfQUFqZ3QtZHVfTEQ1RXB4UmFkVkRmeXduUU1XQzM2YU5Jb002cnNpb01B?oc=5","date":"2024-11-28","type":"trial","source":"prnewswire.com","summary":"Follicular Lymphoma Clinical Trial Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - prnewswire.com","headline":"Follicular Lymphoma Clinical Trial Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Therape","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTE94YVdybTFFY3NVZWhtZDBwX0t3aHlOUEVQOFVPM0lZTXV0Sk9pUjFWb3NTWUdTb2xnRDBYN2YzcGgzTlhYV0lLRU5NX2JEb3k1VnkyakxybjV3VlNYWndPZVhfNmhrT2tDWHctSVFTVndUU1RvTnctWHgyQQ?oc=5","date":"2024-06-27","type":"deal","source":"KED Global","summary":"Eugene PE, KDB PE to acquire Boryung Biopharma for $231 million - KED Global","headline":"Eugene PE, KDB PE to acquire Boryung Biopharma for $231 million","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTFBXZmdjazRZRVhEcHQtM3JudjRqQzhNNDU2VlpfNXhKQkl1MkVmOWVTdC1Ja1BPV3BFZ0pWZkRvdHJKbC1JQXFIaXNfbm1KWDQ4TUxWUDUycHBMRDVDbUJtNkpJZmpRaG0tTnJ3Q2Vn?oc=5","date":"2023-12-20","type":"pipeline","source":"KED Global","summary":"Boryung, HK inno.N to co-market Kanarb, K-CAB - KED Global","headline":"Boryung, HK inno.N to co-market Kanarb, K-CAB","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxNZmZNU3d6UXFlNmJOSlJSSXpIcUZvX2lWUGVSNENVSFZLVWJPR1JkN0lyMmJkRDBFR1o3MVQ4dmdaenhUWXVvZjg2Q1p1YnRMM2g2OS1vbzAzeEhHbDlnSkRzb1JnUnlYTG9YTF9TZkptNkZmTVhQNGVOOHJ5Ny1KcWR3a3ozOWE3a2F1Yi1mamdOLXhheW4tRnpISVRTZw?oc=5","date":"2023-12-13","type":"pipeline","source":"BioWorld News","summary":"Astrazeneca to withdraw diabetes drug Forxiga from Korea - BioWorld News","headline":"Astrazeneca to withdraw diabetes drug Forxiga from Korea","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0AFBVV95cUxNei0xTnJMR29WUUVZX3JXX0RIaE1vWFZXbzNjakQxZHFwMW1xQ05fLWlVZUpPZ3p6TzFaWklnTnh2cTM1QU5sdzBsRGowN2xJdi04MzBUaU5DZjVxc1hiSlRTM2ViSmRnQlY1NHhvanA4cm9KenZ4UWFhMmZPMm9EQXpIU1RidU9CWjFsR0pxV1ZMcWVVNGRELVR3dTBOZUQ2Rk1wWThoT2tCbWNPODFJdDBpYVZmdm9za25UMGd4UHpPVlhOeEdKbkg0MmpOY3N3?oc=5","date":"2020-10-24","type":"pipeline","source":"Reuters","summary":"S.Korean authorities stick to flu vaccine plan after deaths rise to 48 - Reuters","headline":"S.Korean authorities stick to flu vaccine plan after deaths rise to 48","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiV0FVX3lxTE8xeXFWMnNlS1NNb2M1b3BoYlhWUkFEM2hJR1lDRktfcC1BUWJtRy1KQ2NXd3JLN2hHVGZhOEQyaUEwWEM4VWZMTXZXY0IzQ3h1VEVaMF96NA?oc=5","date":"2020-08-12","type":"trial","source":"바이오스펙테이터","summary":"Autotelic Bio expands its management team to accelerate clinical trial for ATB-301 and ASO based platform technology development - 바이오스펙테이터","headline":"Autotelic Bio expands its management team to accelerate clinical trial for ATB-301 and ASO based platform technology dev","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTE02SHhtcTV6UTU3VEg0MkFiSWZQbGpiMXJSVzZBWHZldmtYUXNZSzlVZmR4SUJKVEJHU1BsOXptVHZQTjkxZ3RiVTZMUTZOLWhDY1MzZjBxOVc0UFRVVUJyag?oc=5","date":"2020-08-03","type":"pipeline","source":"Pharmaceutical Executive","summary":"Country Report: Korea - Pharmaceutical Executive","headline":"Country Report: Korea","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxQM1RrM0J6ekF3aUdnQVRvWmNySDdrLWN6Q1hvc2NPcWpxeU9VVmxlUVVoM0R3M09GSlNfdHdVcHQ3NTBRU3p4ZE1YTi1lVlVQOVd5Q3NXY2M4RTBlZXZSSDlzNjhzSncxRU1qcUs2SEJaVERXXzJXSmtWNkxRcWdtUURJMG85bWpDbXlrWUtmZ0p5WE1hZFp1Z2o5UERtT21XQjM5ODltZGprWEs0?oc=5","date":"2019-06-05","type":"pipeline","source":"Cleanroom Technology","summary":"Boryung increases production efficiency with Watson-Marlow Aflex Hose - Cleanroom Technology","headline":"Boryung increases production efficiency with Watson-Marlow Aflex Hose","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxPY01YNHpZZ0taNnF3ZUZHSlN4ZF9CRC1GQVdUYVRZLVUwQU1pSlVael9QMWZVdXNRTjdrVmgyRTdJYTRLRFpwa1VpWWEzQzRkUFpsSjZ0LW01UXA2V0dLdm9hTk45Mm5KdDk0bTBuTUdmT2RRcTNrQUpsR09lLTI5ODYycnRwenBad25SX1l5N1R2dXZ1RkNFQVFEMWZTOVhpZjdmSzZzRjZhMk5vTjZ2OEVn?oc=5","date":"2014-11-30","type":"pipeline","source":"Korea JoongAng Daily","summary":"CEO pushes boundaries of Korean pharmaceuticals - Korea JoongAng Daily","headline":"CEO pushes boundaries of Korean pharmaceuticals","sentiment":"neutral"}],"patents":[],"drugCount":49,"phaseCounts":{"phase_3":25,"phase_2":17,"marketed":5,"phase_1":2},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}